Watchlist Sponsored By :
- Facebook Fiasco: 10 Things Underwriters Got Wrong
- Sticker Shock: What College Is Likely to Cost in 18 Years
- Week Ahead: Europe Has Wall Street Bull on Short Leash
- What Happened to Stocks? Most Unloved in 50 Years
- Icahn Raises Stake in Chesapeake, Wants Board Seats
- Citigroup Lost $20 Million on Facebook IPO Trades
- Break Up JPMorgan: Sheila Bair
- Main Players in the Greek Election
- Many Greeks Moved Their Money Abroad Long Ago
- A New Look at the ‘New Poor’
- Six Pack: Beer Buzz of the Week
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Yoshikami: Four Things You Need to Know About Gold Now
- Steinbock: The Euro Zone Endgame Begins
- Option Bulls Take Another Shot on Idenix
MOST SHARED
- Citigroup Lost $20 Million on Facebook IPO Trades
- Spanish Lender Seeks 19 Billion Euros; Ratings Cut on 5 Banks
- Astronauts Snare SpaceX Rocket
- Carl Icahn Increases Stake in Chesapeake, Demands Board Seats
- Marc Faber: 100% Chance of Global Recession
- The Key to a Successful Turnaround
- Your First Move For Tuesday May 29th
- Oil Declines, but Doesn't Help European Consumers
- Senate Summons Dimon to 'Get to the Bottom' of JPM Mess
- Kansas City Fed President Steps Into Jamie Dimon Debate
MOST POPULAR
HOT ON FACEBOOK
Merck, Schering To Develop Combo Pill With Lipitor
Published:
Monday, 26 Mar 2007 | 12:32 PM ET
Text Size 
By: Reuters
Merck [MRK
Loading...
()
] and Schering-Plough [SGP
Loading...
()
] said on Monday they were beginning development on a cholesterol-lowering product that would combine their Zetia drug with Pfizer's [PFE
Loading...
()
] Lipitor.
The development program is timed so the combination product could be available when the patent for Lipitor, known generically as atorvastatin, expires in the U.S. and
internationally, the companies said.
Lipitor, the world's largest-selling drug, is expected to face generic competition in the U.S. in 2010 or 2011.
Schering-Plough and Merck already have a joint venture to market Zetia and Vytorin, which combines Zetia with Merck's Zocor.
Click for related content
© 2012 CNBC.com
- The Nasdaq has suffered the most from the EU crisis showing there's risk in the usual tech stocks.
- Targeting more Millennials is just one of the items brewing for consumers in the world of spirits.
- It seems many people may need a reminder of how NOT to act on a plane. Here are a few tips.
- Here are some very unusual roadside stops along American highways that might peek your interest.
- How three generations of Americans are dealing with the finances of retirement.
Data is a real-time snapshot *Data is delayed at least 15 minutes
